Medindia

X

QIAGEN Unveils Unique Sample to Insight Solutions for Liquid Biopsies and Hereditary Diseases

Tuesday, October 18, 2016 Research News J E 4
Advertisement
All-in-One library prep kit, plus collection, stabilization and bioinformatics solutions enable NIPT and cancer research

VANCOUVER and HILDEN, Germany, October 17, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAseq® cfDNA All-in-One Kit, combining cell-free DNA extraction and library preparation in the first dedicated solution for liquid biopsy analysis on any next-generation sequencing (NGS) platform. The new kit integrates with QIAGEN's recently launched PAXgene® Blood ccfDNA Tube for collection and stabilization of blood samples, as well as with the market's first bioinformatics workflow for cfDNA also introduced today by QIAGEN, creating a streamlined testing solution that allows faster, more convenient and reliable analysis of cell-free DNA from sample collection to interpreted result.

Furthermore, QIAGEN unveiled an enhanced bioinformatics workflow for hereditary and rare diseases, offering unique capabilities for research using liquid biopsies in non-invasive prenatal testing (NIPT) as well as cancer biomarker discovery. QIAGEN is rolling out the solutions at the American Society of Human Genetics ASHG 2016 Annual Meeting in Vancouver.

Click here for the full press release

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={55CA9831-FA0A-4520-8B26-FA269E7F1FE6}&lang=en

Contacts 

Public Relations:  Dr. Thomas Theuringer Senior Director Public Relations +49-2103-29-11826

Email: pr@qiagen.com http://www.twitter.com/qiagen https://www.facebook.com/QIAGEN pr.qiagen.com

Investor Relations:  John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email: ir@qiagen.com ir.qiagen.com

SOURCE QIAGEN N.V.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Veracyte Releases Preliminary Third Quarter 2016 F...
S
Northwestern Memorial Hospital Ranked First in Nat...